Meeting
2011 ASCO Annual Meeting
Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer.
Authors
A. Rocca
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
A. Rocca , A. Paradiso , P. Sismondi , E. Scarpi , A. Mangia , L. Medri , S. Bravaccini , D. Casadei Giunchi , D. Amadori , R. Silvestrini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer - Triple-negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT01031030
Citation
J Clin Oncol 29: 2011 (suppl; abstr 1031)
Abstract #
1031
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Safety and tolerability of adjuvant dose dense chemotherapy in elderly patients with node-positive early breast cancer.
First Author: Vasilios Karavasilis
First Author: Begoña Bermejo
Poster
2013 ASCO Annual Meeting
Impact of body mass index (BMI) on the prognosis of women with high-risk early breast cancer (BC) receiving adjuvant chemotherapy (CT).
First Author: Alessandra Gennari
Poster
2013 ASCO Annual Meeting
Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2).
First Author: Volker Moebus